A total of
Retacrit has not been shown to be interchangeable with U.S.-licensed Epogen/Procrit. of darbepoetin administered SC has been shown in cancer patients
contracts, darbepoetin alfa is less expensive than epoetin alfa.
FDA approves first epoetin alfa biosimilar for the treatment of anemia Epogen (epoetin alfa)injection, for intravenous or subcutaneous use Initial U.S.Approval: 1989 WARNING:ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE See full prescribing information for complete boxed warning. This site is intended only for U.S. healthcare professionals. Before sharing sensitive information, make sure you're on a federal government site. a half-life of 25.3 hours compared to epoetin alfa, which has a
May 15, 2018.
Pharmacotherapy Update - Automatic Therapeutic Interchange Program If a serious allergic reaction occurs, appropriate therapy should be administered, with close patient follow-up over several days. in Hgb of 2 g/dL from baseline. Available for Android and iOS devices. Note: The manufacturer states that, until efficacy/toxicity parameters are established, the use of oprelvekin in pediatric patients (particularly those <12 years of age) should be restricted to use in controlled clinical trials. Estimated Aranesp Starting Doses (mcg/week) for Patients with CKD on Dialysis Based on Previous Epoetin alfa Dose (Units/week), Previous Weekly Epoetin alfa Dose (Units/week). Vol.
Check again for air bubbles.
What is the practical conversion dose when changing from epoetin alfa arena for dosing, dosing interval, hemoglobin levels, number of
IL-11 has also been shown to have non-hematopoietic activities in animals including the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis, inhibition of pro-inflammatory cytokine production by macrophages, and the stimulation of osteoclastogenesis and neurogenesis. The majority of reported events occurred upon initial exposure. The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic . eCollection 2017. Clipboard, Search History, and several other advanced features are temporarily unavailable. \v0!(?kX }y}3Q6bj>CMOaf&Uhzttxr"m- q! RETACRIT single-dose vials contain phenylalanine, a component of aspartame. To report an adverse event, please call 1-800-438-1985. HHS Vulnerability Disclosure, Help Northwest Kidney Centers Home Dialysis Programs Standing Orders - Erythropoietin . In patients who are receiving epoetin alfa once weekly, darbepoetin should be administered once every 2 weeks. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare? deemed epoetin alfa (Procrit; OrthoBiotech) and darbepoetin
The dose conversion depicted in Table 1 does not accurately estimate the once monthly dose of Aranesp. Conversion from Epoetin alfa to Aranesp in patients with CKD on dialysis.
RETACRIT Instructions For Use (epoetin alfa-epbx) The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial.
PDF Highlights of Prescribing Information ------------------dosage and Pronai W, Neyer U, Barnas U, Wieser C, Jaeger C, Dekic D, Hemetsberger M, Rosenkranz AR. transfusions, and iron studies. When therapy with RETACRIT is needed in these patient populations, use single-dose vials; do not admix with bacteriostatic saline containing benzyl alcohol, In controlled clinical trials of patients with chronic kidney disease (CKD) comparing higher hemoglobin targets (13 - 14 g/dL) to lower targets (9 - 11.3 g/dL), epoetin alfa increased the risk of death, myocardial infarction, stroke, congestive heart failure, thrombosis of hemodialysis vascular access, and other thromboembolic events in the higher target groups, Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit. Recommended regimens for patients undergoing elective, noncardiac, nonvascular surgery, 300 Units/kg per day SC for 15 days total: administered daily for 10 days before surgery, on the day of surgery, and for 4 days after surgery, 600 Units/kg SC in 4 doses, administered 21, 14, and 7 days before surgery and on the day of surgery. Increase dose by 50-100 units/kg 3 times/week if response is not satisfactory in terms of reducing transfusion requirements or increasing hemoglobin after 8 weeks of therapy. . Refer to Table 1. July/August 2004, Return to
1.4 Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy ZARXIO is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [see Clinical Studies (14.4)]. Previous dosage of epoetin alfa: 5000-10,999 units/week,then darbepoetin alfa dosage: 25 mcg/week. For the purposes of this policy, a conversion factor of 3 should be used to estimate hematocrit when only the hemoglobin is measured, e.g., hemoglobin of 10 g . See full prescribing information for RETACRIT. Discontinue treatment with oprelvekin >/= 2 days before starting the next planned cycle of chemotherapy. Cases A, Portols J, Calls J, Martinez-Castelao A, Munar MA, Segarra A. Int Urol Nephrol. Children: 75-100 mcg/kg once daily for 10-21 days (until postnadir platelet count >/= 50,000 cells/ uL). In the event that ARDS occurs, Neulasta should be discontinued and/or withheld until resolution of ARDS and patients should receive appropriate medical management for this condition. Epub 2014 Jan 31. This site complies with the HONcode standard for trust- worthy health information: verify here.
If patient does not respond, a response to higher doses is unlikely. Epub 2009 Aug 4.
PDF All Orders Must Be Marked in Ink With a Checkmark to Be Active. - Ohsu Alternative dose: 600 units/kg in once weekly doses (21, 14, and 7 days before surgery) plus a fourth dose on the day of surgery. 2.25 mcg/kg every week subcutaneously until completion of a chemotherapy course. Slowly push the plunger up to force the air bubbles out of the syringe.
RETACRIT Dosage and Administration (epoetin alfa-epbx) e.g., 4 x 20 mcg of darbepoetin alfa per week/0.55 = 145.5 mcg of Mircera once every 4 weeks. 0 Overall, only 10.5% of patients had iron studies before erythropoietin
every-other-week) for darbepoetin alfa-treated patients.
Amgen Adverse effects on PFS and/or OS were observed in studies of patients receiving chemotherapy for breast cancer, lymphoid malignancy, and cervical cancer; in patients with advanced head and neck cancer receiving radiation therapy; and in patients with non-small cell lung cancer or various malignancies who were not receiving chemotherapy or radiotherapy, RETACRIT is contraindicated in patients with uncontrolled hypertension. Based on data from this CCHS DUE, darbepoetin alfa and
Can J Kidney Health Dis. For adult patients with CKD not on dialysis: When treating patients who have chronic kidney disease and cancer, physicians should refer to Warnings and Precautions (5.1 and 5.2). Do not use any vials or prefilled syringes exhibiting particulate matter or discoloration. %PDF-1.5
Darbepoetin alfa, although several fold more biologically
e.g., 4 x 1500 Units of epoetin alfa per week/125 = 48 mcg of Mircera once every 4 weeks. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. MeSH The FDA granted approval of Retacrit to Hospira Inc., a Pfizer company. Note: In patients receiving epoetin alfa 2-3 times per week, darbepoetin alfa is administered once weekly.In patients who are receiving epoetin alfa once weekly, darbepoetin should be administered once every 2 weeks. CHO chains) has a 3-fold increase in half-life when compared to
<>
and approved an automatic therapeutic interchange to darbepoetin
4 x previous weekly darbepoetin alfa dose (mcg)/0.55.
What is the difference between Retacrit and Procrit? - Drugs.com OMONTYS has not been shown to improve symptoms, physical functioning or health-related quality of life. Neulasta should be permanently discontinued in patients with serious allergic reactions. Conclusion: Both drugs are costly: January 2003 prices posted by Medicare put reimbursement rates at $12.69 per 1000 units of Procrit (translating to about $534.32 for the Average Wholesale Price [AWP] for a once-a-week dose of 40,000 units) and $23.69 per 5 micrograms of Aranesp (about $994.98 for the AWP for a 3 mcg/kg dose every other week). maintain desired hemoglobin (Hgb) levels. Non-hematopoietic pathologic changes observed in animals include fibrosis of tendons and joint capsules, periosteal thickening, papilledema, and embryotoxicity. Following initiation of therapy and after each dose adjustment, monitor hemoglobin weekly until the hemoglobin level is stable and sufficient to minimize the need for RBC transfusion. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). 2007 Apr;12(2):126-9. doi: 10.1111/j.1440-1797.2006.00762.x. When initiating or adjusting therapy, monitor hemoglobin levels at least weekly until stable, then monitor at least monthly. Refer to Aranesp package insert for pediatric dosing conversion. Following initiation and titration of epoetin alfa, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving RETACRIT, Appropriately control hypertension prior to initiation of and during treatment with RETACRIT. 7/2021: added Epogen (nonformulary). Only physicians qualified by specialized training or experience in the treatment of patients with sickle cell disease should prescribe Neulasta for such patients, and only after careful consideration of the potential risks and benefits. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
PDF Aranesp, Epogen, Mircera, Procrit, Retacrit - Cigna Dosage adjustment: Goal: Dose should be adjusted to achieve and maintain a target hemoglobin not to exceed 12 g/dL. Based on market share
government site. Dr. Gerald Diaz @GeraldMD. This site needs JavaScript to work properly. Leukocytosis (white blood cell counts 100,000/mm3 ) has been observed in <1% of patients receiving pegfilgrastim. RETACRIT is a registered trademark of Pfizer Inc. Epogen is a registered trademark of Amgen Inc. Procrit is a registered trademark of Janssen Products, LP. 2006 Jan;40(1):58-65; quiz 169-70. doi: 10.1345/aph.1G042.
The maximum number of administrations of Aranesp for a billing cycle is 5 times in 30/ 31days. Avoid frequent dose adjustments. Both Retacrit and Procrit are approved for treatment of anemia caused by chronic kidney disease, chemotherapy, use of zidovudine in patients with HIV, and before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery. Before Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDAs MedWatch Reporting System or by calling 1-800-FDA-1088. 4. 2014 Mar;164(5-6):109-19. doi: 10.1007/s10354-013-0256-7. Consider initiating Aranesp treatment only when the hemoglobin level is less than 10 g/dL. 4. interchange, such as patients with chronic renal failure (CRF). for epoetin alfa-treated patients and 200 mcg every 2 weeks (or
FDA Approved Indication(s) Epogen, Procrit, and Retacrit are indicatedfor: Treatment of anemia due to: o Chronic kidney disease (CKD) in patients on dialysis and not on dialysis RETACRIT Dosage Forms and Strengths (epoetin alfa-epbx) 3 DOSAGE FORMS AND STRENGTHS Injection: 2,000 Units/mL, 3,000 Units/mL, 4,000 Units/mL, 10,000 Units/mL, and 40,000 Units/mL of RETACRIT as a clear and colorless liquid in single-dose vials. dose of darbepoetin alfa for CIA is 200 mcg SC every-other-week
The optimal timing and duration of growth factor stimulation has not been determined. erythropoietin, darbepoetin alfa stimulates erythropoiesis. ferrous sulfate, Procrit, Retacrit, epoetin alfa, Epogen, darbepoetin alfa. On May 15, 2018, the Food and Drug Administration approved Retacrit (epoetin alfa-epbx, Hospira Inc., a subsidiary of Pfizer Inc.) as a biosimilar to Epogen/Procrit (epoetin alfa, Amgen Inc.) for . No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. The most frequent dosing regimens were 40,000 units weekly
Please review the latest applicable package insert for additional information and possible updates. Conversion from another ESA: dose once monthly based on the total weekly epoetin or darbepoetin alfa dose at the time of conversion. Administer Aranesp once every 2 weeks in patients who were receiving epoetin alfa once weekly. Existing patients on IV EPO, change to subcutaneous EPO using the . 2004 May;19(5):1224-30. doi: 10.1093/ndt/gfh106. Update Index. Pfizer for Professionals 1-800-505-4426 The dose conversion depicted in Table 1 does not accurately estimate the once monthly dose of Aranesp. 4 0 obj
DOSAGE AND ADMINISTRATION Initial treatment: 0.04 mg/kg body weight administered once monthly. : RaPL6!0 )KQml)D$ xCdmuJNI&"zS4j#INdh Aranesp Dosing and Conversion Brochure. Adult Respiratory Distress Syndrome (ARDS) Adult respiratory distress syndrome (ARDS) has been reported in neutropenic patients with sepsis receiving Filgrastim, the parent compound of Neulasta, and is postulated to be secondary to an influx of neutrophils to sites of inflammation in the lungs. Epub 2005 Dec 6. 335 0 obj
<>stream
PDF Policy Title: Erythropoiesis stimulating agents: Retacrit (epoetin alfa Epoetin alfa-epbx (Retacrit) will be approved through clinical review up to a 12-month determination. The conversion rate was 354:1 in patients requiring high (>200 IU/kg/week) doses of epoetin and 291:1 in patients requiring low doses. M(aOf}c^gw+&=s=O{+h5ACmVA;8*=vSO`8dmD}a"'3L
DMr7GwG 3\\q'z .MreQlX`DWxxxnU@!TUrTng_wAMc`0N[P Si)i+j(1A%@xaB&Zx03\'O.h` &!T6. 0*ET*LQjH!z!6G OsI`~ RETACRIT (epoetin alfa-epbx) is biosimilar* to EPOGEN/PROCRIT (epoetin alfa) WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE . . Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. More specifically, 23 patients in the epoetin alfa group
Martnez Castelao A, Reyes A, Valds F, Otero A, Lpez de Novales E, Pallard L, Tabernero JM, Hernndez Jaras J, Llads F. Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T; German Aranesp Study Group. Initiate Aranesp treatment when the hemoglobin level is less than 10 g/dL. The products discussed in this site may have different product labeling in different countries. The
Methods: All in-centre haemodialysis patients (n = 60) were converted from an existing subcutaneous epoetin alfa regimen to weekly intravenous darbepoetin alfa.
RETACRIT (epoetin alfa-epbx) Dosing Info | Safety Info - Pfizer pro The .gov means its official.Federal government websites often end in .gov or .mil. Aranesp is a medicine used to treat anaemia (low red blood cell counts) that is causing symptoms. affinity has no or little clinical relevance. Nephrology (Carlton). Contributed by. dvO*g%6u7Gw~A%a^7lW^{^6Vk?u^Gn"2@^n?0NS.OpJ
Vu],Ne,z8yT&6Qb6b=bk?+e/d`yo;~B#"z*wd j23#M]\"LFEB(hHQlD5h*}TJwlL{A
PRCA has also been reported in patients receiving ESAs for anemia related to hepatitis C treatment (an indication for which RETACRIT is not approved). this interchange program should be directed to the CCF Department
33 Dose.
Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta In the absence of PRCA, follow dosing recommendations for management of patients with an insufficient hemoglobin response to RETACRIT therapy, Cases of PRCA and of severe anemia, with or without other cytopenias that arise following the development of neutralizing antibodies to erythropoietin have been reported in patients treated with epoetin alfa. In addition, Hgb levels were
*For pediatric patients receiving a weekly epoetin alfa dose of < 1,500 Units/week, the available data are insufficient to determine an Aranesp conversion dose. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery. A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis. Do not re-enter vial. <> In addition, as with Epogen/Procrit, Retacrit contains a Boxed Warning to alert health care professionals and patients about increased risks of death, heart problems, stroke and tumor growth or recurrence. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Would you like email updates of new search results? National Institutes of Health, U.S. National Library of Medicine, DailyMed Database. Questions regarding
CONTRAINDICATIONS Neumega is contraindicated in patients with a history of hypersensitivity to Neumega or any component of the product, Dosage SubQ: Note: First dose should not be administered until 24-36 hours after the end of chemotherapy. Dosing: Dosing, even in morbidly obese patients, should be based on actual body weight. 2014 Oct;46(10):1983-95. doi: 10.1007/s11255-014-0800-4. of the molecule is a more important determinant of potency and receptor
An official website of the United States government. Inclusion Criteria: - Subjects who are greater than 6 months post-renal transplant (living or cadaveric) - Using adequate contraceptive precaution, if of childbearing potential - Available for follow-up assessments and dosing visits - Hb concentration less than 11.0 g/dL within 3 months of screening and a hemoglobin concentration less than 11.0 during the screening period Exclusion Criteria . Depending upon each patient's needs and response, dosage
The original dosage reduction after the switch from epoetin alfa to weekly intravenous darbepoetin alfa may offset the increased relative cost of the latter. Patients on Cancer Chemotherapy Initiate Aranesp in patients on cancer chemotherapy only if the hemoglobin is less than 10 g/dL, and if there is a minimum of two additional months of planned chemotherapy. <>
Background: RETACRIT is contraindicated in patients with: RETACRIT from multiple-dose vials contains benzyl alcohol and is contraindicated in: INCREASED MORTALITY, MYOCARDIAL INFARCTION, STROKE, AND THROMBOEMBOLISM, INCREASED MORTALITY AND/OR INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE IN PATIENTS WITH CANCER, LACK OR LOSS OF HEMOGLOBIN RESPONSE TO RETACRIT, RISK OF SERIOUS ADVERSE REACTIONS DUE TO BENZYL ALCOHOL PRESERVATIVE, ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE, ANEMIA DUE TO CHEMOTHERAPY IN PATIENTS WITH CANCER, ANEMIA DUE TO ZIDOVUDINE IN PATIENTS WITH HIV INFECTION, Recommended dosing for adults and children with chronic kidney disease (CKD), The recommended starting dose for adult patients is 50 to 100 Units/kg 3 times weekly intravenously (IV) or subcutaneously (SC). patients and 55 darbepoetin alfa patients. If hemoglobin continues to increase, hold dose temporarily until hemoglobin begins to decrease, then restart at a dose 25% below the previous dose. Use caution in patients with coexistent cardiovascular disease and stroke. PenTAG FINAL PROTOCOL 2 darbepoetin alfa (Aranesp [Amgen]). Severe sickle cell crises, in some cases resulting in death, have also been associated with Filgrastim, the parent compound of pegfilgrastim. Hypertension: Control hypertension prior to initiating and during treatment with OMONTYS. Approved by FMOLHS P&T. . 2007 Aug;23(8):1931-7. doi: 10.1185/030079907X210705. Each 1 mL single-dose vial of 2,000, 3,000, 4,000, 10,000, and 40,000 Units of epoetin alfa-epbx injection contains 0.5 mg of phenylalanine.
Neumega is not indicated following myeloablative chemotherapy (see package insert for WARNINGS, Increased Toxicity Following Myeloablative Therapy). Administer Aranesp once weekly in patients who were receiving epoetin alfa 2 to 3 times weekly. A local search option of this data can be found here.
PDF Aranesp (Darbepoetin alfa) Label - Food and Drug Administration Dosage SubQ: Adolescents >45 kg and Adults: 6 mg once per chemotherapy cycle; do not administer in the period between 14 days before and 24 hours after administration of cytotoxic chemotherapy; do not use in patients, infants, children, and smaller adolescents weighing <45 kg. If patient has not responded satisfactorily to a 300 unit/kg dose 3 times/week, a response to higher doses is unlikely. Biological products are generally derived from a living organism and can come from many sources, such as humans, animals, microorganisms or yeast. Myelosuppressive therapy: 5 mcg/kg/day - doses may be increased by 5 mcg/kg according to the duration and severity of the neutropenia.
ARANESP (darbepoetin alfa) Co-pay Card and Cost Assistance epoetin alfa produce similar Hgb levels in patients with CIA. 2017 Jun 30;4:2054358117716461. doi: 10.1177/2054358117716461. Overall, in both groups iron studies were not conducted routinely. <>/ExtGState<>/XObject<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>>
The recommended starting dose and schedules are: Self-Administration of the Prefilled Syringe. ChronicKidney Disease: at the Cleveland Clinic Health System (CCHS) reviewing the use of
An official website of the United States government, :
Switch from epoetin to darbepoetin alfa in hemodialysis: dose Monitor platelets and hematocrit regularly. Resources for Information | Approved Drugs, Recalls, Market Withdrawals and Safety Alerts, Resources for Information | Approved Drugs, Oncology (Cancer) / Hematologic Malignancies Approval Notifications, Verified Clinical Benefit | Cancer Accelerated Approvals, Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description, FDA approves Retacrit as a biosimilar to Epogen/Procrit, Drug Information Soundcast in Clinical Oncology. 8600 Rockville Pike If typical causes of lack or loss of hemoglobin response are excluded, evaluate for PRCA. When administered weekly and intravenously, darbepoetin alfa maintains Hb at a more favourable conversion rate than is currently recommended. Inadequate response: Hemoglobin increases <1 g/dL over 4 weeks . The most common dosing regimens are 40,000 units weekly for epoetin alfa and 200 mcg every 2 weeks for darbepoetin alfa. Unable to load your collection due to an error, Unable to load your delegates due to an error. Mechanism of Action: Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation differentiation commitment and some end-cell functional activation. Additional warnings include high blood pressure, seizures, a condition in which the bone marrow stops making red blood cells thus causing anemia, serious allergic reactions and severe skin reactions. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known, Phenylalanine can be harmful to patients with phenylketonuria (PKU). 4y\@:hT4\j
EvZ%fN1gtL|;`,% \ZPrC|.CtI8K,f^f#.PJ#|CZx~igq\jA@PPq. Immediately and permanently discontinue RETACRIT and administer appropriate therapy if a serious allergic or anaphylactic reaction occurs, Blistering and skin exfoliation reactions, including erythema multiforme and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), have been reported in patients treated with ESAs (including epoetin alfa) in the postmarketing setting.